2021
Diverse functional autoantibodies in patients with COVID-19
Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, Zhou T, Israelow B, Wong P, Coppi A, Lucas C, Silva J, Oh JE, Song E, Perotti ES, Zheng NS, Fischer S, Campbell M, Fournier JB, Wyllie AL, Vogels CBF, Ott IM, Kalinich CC, Petrone ME, Watkins AE, Dela Cruz C, Farhadian S, Schulz W, Ma S, Grubaugh N, Ko A, Iwasaki A, Ring A. Diverse functional autoantibodies in patients with COVID-19. Nature 2021, 595: 283-288. PMID: 34010947, DOI: 10.1038/s41586-021-03631-y.Peer-Reviewed Original ResearchConceptsPeripheral immune cell compositionSARS-CoV-2 infectionCOVID-19Effects of autoantibodiesTissue-associated antigensSpecific clinical characteristicsInnate immune activationImmune cell compositionCOVID-19 exhibitCOVID-19 manifestsAnalysis of autoantibodiesSARS-CoV-2Functional autoantibodiesMouse surrogateClinical characteristicsVirological controlClinical outcomesImmune activationMild diseaseAsymptomatic infectionAutoantibody reactivityDisease progressionHealthcare workersHigh prevalenceAutoantibodies
2020
Sex differences in immune responses that underlie COVID-19 disease outcomes
Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, Silva J, Mao T, Oh JE, Tokuyama M, Lu P, Venkataraman A, Park A, Liu F, Meir A, Sun J, Wang EY, Casanovas-Massana A, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ, Shaw A, Fournier J, Odio C, Farhadian S, Dela Cruz C, Grubaugh N, Schulz W, Ring A, Ko A, Omer S, Iwasaki A. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 2020, 588: 315-320. PMID: 32846427, PMCID: PMC7725931, DOI: 10.1038/s41586-020-2700-3.Peer-Reviewed Original ResearchConceptsInnate immune cytokinesFemale patientsMale patientsImmune cytokinesDisease outcomeImmune responseCOVID-19COVID-19 disease outcomesPoor T cell responsesSARS-CoV-2 infectionSevere acute respiratory syndrome coronavirusAcute respiratory syndrome coronavirusSex-based approachModerate COVID-19Sex differencesRobust T cell activationT cell responsesWorse disease progressionWorse disease outcomesHigher plasma levelsNon-classical monocytesCoronavirus disease 2019T cell activationImmunomodulatory medicationsPlasma cytokines
2018
Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
Hulshof L, Overbeek SA, Wyllie AL, Chu MLJN, Bogaert D, de Jager W, Knippels LMJ, Sanders EAM, van Aalderen WMC, Garssen J, Land B, Sprikkelman AB, Group T, Blauw A, Dontje B, Duijvestein Y, de Boom W, Groot I, Boks M, van Kooyk Y, Fandri D, Hijnen D, Middelkamp-Hup M, Papi B, Roelofs M, Rijnierse A, Veening D, Support C, Prakken B, Tusscher G, Tupker R, Willemsen L. Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis. Frontiers In Immunology 2018, 9: 630. PMID: 29966024, PMCID: PMC5884950, DOI: 10.3389/fimmu.2018.00630.Peer-Reviewed Original ResearchConceptsSevere atopic dermatitisAtopic dermatitisDietary interventionAD severityCommon chronic inflammatory skin diseaseT helper cell type 2Understanding of ADChronic inflammatory skin diseaseCC chemokine ligand 17CXC chemokine ligand 9Serum chemokine levelsSpecific IgE levelsInflammatory skin diseaseChemokine ligand 17Cell type 2Dietary intervention studyWhey-based formulaChemokine ligand 9Post-intervention samplesMonths of ageCCL22 chemokinesTh1 chemokinesTh2 chemokinesChemokine levelsM-16V